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Background: The skin and soft tissue infections (SSTIs) increase represents a major concern in both community
and hospital setting, carrying a significant economic burden, as well as morbidity and mortality, especially when
caused by methicillin-resistant Staphylococcus aureus (MRSA). Dalbavancin (DAL), a lipoglycopeptide, is indicated
for the treatment of SSTIs, and has a broad spectrum of action against most microorganisms, including those
resistant to other antimicrobials. The aim of this study was to determine the straightforward performance of DAL
upon the binomial antibiotic resistant staphylococci and host defenses, to establish its potential
immunomodulating activity.
Materials/methods: DAL effect (at 1xMIC or 2xMIC) on human polymorphonuclear cells (PMNs) functional
activities (microbicidal activity and cytokine release profile) was investigated by incubating MRSA and phagocytes
for different incubation times. To differentiate between any separate effect of DAL on the bacteria and PMNs, in
vitro DAL pretreatment assays were also performed by the exposure of each of them to DAL (at 1xMIC) for 1 h,
before they were incubated together.
Results: Our results evidenced in DAL presence an enhanced MRSA killing activity by PMNs in comparison with
DAL-free controls, within 90 minutes of incubation. In fact, in control condition PMNs were able to scanty kill
ingested MRSA, whereas with the addition of DAL at 1xMIC or 2XMIC, significantly (p<0.01) enhanced their
staphylococcal killing (Figure 1A). The assays with DAL pre-treated MRSA or PMNs highlighted a similar trend: an
improved staphylococcal killing due to DAL direct effect on both staphylococci and PMNs within 90 minutes of
incubation (Figure 1 B). In parallel a decreased level of TNF-α was observed in DAL-treated PMNs in presence of
MRSA.
Conclusions: Neutrophil-mediated killing is a crucial defense system against S. aureus, however the pathogen has
evolved many strategies to resist killing. In the present study, we highlighted that DAL acts in synergism with
neutrophils by modulating both staphylococcal killing and cytokine release. A role of TNF in apoptosis regulation
has been observed that could indirectly influence the killing capacity. These preliminary results draw attention to
the need of a deeper understanding of the mechanisms exerted by DAL on neutrophil functional activities.
29TH ECCMID
13-16 APRIL 2019 AMSTERDAM, NETHERLANDS 
POWERED BY M-ANAGE.COM 
